Unichem Lab gets tentative nod from USFDA for hydrochloride medicines
Category: #health  By Mateen Dalal  Date: 2019-05-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

Unichem Lab gets tentative nod from USFDA for hydrochloride medicines

These tablets are indicated for nasal decongestant and antihistamine

Unichem may produce and market the generic drug products after approval

Reports confirm that Unichem Laboratories has been granted a tentative ANDA approval by the United States Food and Drug Administration (USFDA) for Unichem's Pseudoephedrine Hydrochloride and Cetirizine Hydrochloride Extended-Release Tablets USP, in the strengths of 120 mg/ 5mg.

Apparently, the firm would be marketing a generic version of Johnson & Johnson’s  Zyrtec-D 12 Hour extended tablets (Pseudoephedrine Hydrochloride/Cetirizine Hydrochloride, 120mg/5 mg). These tablets are indicated for nasal decongestant and antihistamine. On receipt of final approval, the product will be commercialized from Unichemls Goa Plant.

ANDA, or Abbreviated New Drug Approval, is a kind of application in U.S. for a generic drug approval for a currently licensed approved drug. After approval, the company may produce and market the generic drug products.

On the day of the news, the shares of Unichem Laboratories were trading at Rs 188.50, which a Rs 2.15 or 1.15% hike over previous day closing at Rs 186.35. The scrip reportedly opened at Rs. 186.35 and registered a high of Rs 189.95 and a low of Rs. 185.50, with the market capitalization of the company being around Rs 1,311.59 crores.

In the previous year, Unichem Laboratories had informed that its active pharmaceutical ingredient manufacturing units at Roha and Pithampura had received Establishment Inspection Reports from the United States Food and Drug Administration (USFDA). This specified the closure of inspections at the both the plant. The inspection at Roha unit was held between July 30 and August 3 while inspection at Pithampura unit was held between July 23 to July 27.

For the uninitiated, Unichem Laboratories Limited is an international, specialty pharmaceutical company. It is engaged in producing and marketing of pharmaceutical formulations as branded generics and in various markets globally. In India, the company is leading in niche therapy zones of neurology, cardiology, anti-infectives, and orthopedics. The company excels in manufacturing of complex API and dosage forms, process chemistry, as well as in product development.

 

Source Credit: https://www.business-standard.com/article/news-cm/unichem-laboratories-receives-approval-from-usfda-for-hydrocloride-tablets-119050700345_1.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
By Mateen Dalal

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristo...

LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
LifeSpan Bio acquires Everest Biotech to expand reagent portfolio
By Mateen Dalal

The transaction will be LifeSpan BioSciences’ second investment this year following its Nordic-MUbio acquisition LifeSpan BioSciences (LSBio), a provider of life science research reagents and antibodies, has recently announced that it has acqu...

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...